Key terms
About TSVT
2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TSVT news
Mar 20
5:32pm ET
2seventy bio Reinforces Board, Faces Engine Capital Nominations
Mar 18
7:15am ET
TD Cowen Sticks to Its Hold Rating for 2seventy bio (TSVT)
Mar 18
7:12am ET
2seventy bio CSO Exits, Abecma Advances with FDA Committee
Mar 15
7:00pm ET
2seventy bio trading resumes
Mar 15
6:30pm ET
Bristol Myers, 2seventy Bio: FDA’s ODAC votes in favor of Abecma
Mar 15
1:00pm ET
2seventy bio trading halted, news pending
Mar 14
7:36am ET
TD Cowen Sticks to Their Hold Rating for 2seventy bio (TSVT)
Mar 14
7:17am ET
Optimistic Outlook for 2seventy bio’s ABECMA Ahead of FDA Panel Review: A Buy Rating Justified
Mar 06
11:20pm ET
Buy Rating Affirmed for 2seventy bio on FDA Meeting and Strong Financial Outlook
Mar 06
6:31am ET
Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), 2seventy bio (TSVT)
Mar 06
6:22am ET
2seventy Bio price target lowered to $12 from $20 at Canaccord
Mar 05
7:32am ET
2seventy Bio: Abecma generated $56M U.S. commercial revenue in Q4
Mar 05
7:28am ET
2seventy bio: Close of asset sale to Regeneron seen in 1H24
Mar 05
7:19am ET
2seventy Bio reports Q4 EPS ($1.11), consensus (99c)
Feb 06
4:11am ET
2seventy bio and BMS Schedule FDA Panel for Abecma
Feb 05
7:02am ET
Bristol Myers and 2seventy Bio’s application for Abecma to be reviewed by FDA
Feb 03
12:47pm ET
Buy Rating Affirmed for 2seventy bio Amidst Revenue Stabilization and Strategic Growth Initiatives
Jan 31
7:33am ET
2seventy Bio upgraded to Outperform at Leerink on acquisition potential
Jan 31
7:20am ET
2seventy Bio upgraded to Outperform from Market Perform at Leerink
Jan 30
4:24pm ET
2seventy Bio cut to Market Perform at TD Cowen as outlook hinges on Abecma
Jan 30
4:18pm ET
2seventy Bio downgraded to Market Perform from Outperform at TD Cowen
Jan 30
7:23am ET
2seventy Bio names Chip Baird CEO, Vicki Eatwell CFO upon transaction closing
Jan 30
7:17am ET
2seventy Bio to focus on Abecma commercialization with Bristol Myers Squibb
Jan 30
7:04am ET
Regeneron forms Regeneron Cell Medicine amid acquisition of 2seventy platforms
No recent news articles are available for TSVT
No recent press releases are available for TSVT
TSVT Financials
Key terms
Ad Feedback
TSVT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TSVT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range